Cargando…

Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis

INTRODUCTION: The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung cancer (NSCLC) with EGFR+ mutations. However, most patients develop resistance, with the result that median progression-fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batson, Sarah, Mitchell, Stephen A, Windisch, Ricarda, Damonte, Elisabetta, Munk, Veronica C, Reguart, Noemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426468/ https://www.ncbi.nlm.nih.gov/pubmed/28503070 http://dx.doi.org/10.2147/OTT.S134382

Ejemplares similares

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
por: Su, Vincent Yi-Fong, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines
por: Torrisi, Filippo, et al.
Publicado: (2020)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen, Kim-Son H, et al.
Publicado: (2012)

Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
por: Wang, Shouzheng, et al.
Publicado: (2019)

Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis
por: Hu, Lingbo, et al.
Publicado: (2023)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
por: Holleman, Marscha S, et al.
Publicado: (2019)

Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition
por: Caffa, Irene, et al.
Publicado: (2015)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
por: Su, Po‐Lan, et al.
Publicado: (2020)

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
por: Wang, Xiao-Shan, et al.
Publicado: (2022)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
por: Oh, Byeongsang, et al.
Publicado: (2014)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
por: Petrazzuolo, Adriana, et al.
Publicado: (2022)

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key
por: Thomas, Quentin Dominique, et al.
Publicado: (2023)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer
Publicado: (2023)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
por: Ishihara, Hiroki, et al.
Publicado: (2017)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
por: Catlett, Ian M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mriqv2pomgoqv8ckuqbdoolon2